1 521

Cited 8 times in

Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract

DC Field Value Language
dc.contributor.author정병하-
dc.contributor.author조강수-
dc.contributor.author홍성준-
dc.date.accessioned2015-04-23T16:56:40Z-
dc.date.available2015-04-23T16:56:40Z-
dc.date.issued2010-
dc.identifier.issn0042-1138-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/101527-
dc.description.abstractOBJECTIVE: To evaluate the comparative efficacy of adjuvant gemcitabine and cisplatin (GC) chemotherapy between patients with locally advanced transitional cell carcinoma (TCC) of the bladder and upper urinary tract. PATIENTS AND METHODS: From 2001 to 2005, we retrospectively selected a total of 64 patients with locally advanced TCC of the bladder and upper urinary tract who received at least 3 cycles of adjuvant GC chemotherapy. We compared disease-free and overall survival between the 2 groups. RESULTS: The recurrence rate was 30.3% in TCC of the bladder and 25.8% of the upper urinary tract (p = 0.633). Statistical analysis revealed that there was no significant difference in the disease-free or overall survival rate between TCC of the bladder and upper urinary tract treated with adjuvant GC chemotherapy. CONCLUSION: Under the circumstances of limited data about TCC of the upper urinary tract, this study may suggest that adjuvant GC chemotherapy in locally advanced TCC of the upper urinary tract is as effective as those of bladder.-
dc.description.statementOfResponsibilityopen-
dc.format.extent47~51-
dc.relation.isPartOfUROLOGIA INTERNATIONALIS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic CombinedChemotherapyProtocols/adverse effects-
dc.subject.MESHAntineoplastic CombinedChemotherapyProtocols/therapeutic use*-
dc.subject.MESHCarcinoma,TransitionalCell/drug therapy*-
dc.subject.MESHCarcinoma,TransitionalCell/mortality-
dc.subject.MESHCarcinoma,TransitionalCell/pathology-
dc.subject.MESHCarcinoma,TransitionalCell/surgery-
dc.subject.MESHChemotherapy,Adjuvant-
dc.subject.MESHChi-Square Distribution-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/analogs & derivatives-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Invasiveness-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment-
dc.subject.MESHRisk Factors-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHUrinaryBladderNeoplasms/drug therapy*-
dc.subject.MESHUrinaryBladderNeoplasms/mortality-
dc.subject.MESHUrinaryBladderNeoplasms/pathology-
dc.subject.MESHUrinaryBladderNeoplasms/surgery-
dc.subject.MESHUrologic Neoplasms/drug therapy*-
dc.subject.MESHUrologic Neoplasms/mortality-
dc.subject.MESHUrologic Neoplasms/pathology-
dc.subject.MESHUrologic Neoplasms/surgery-
dc.titleEfficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨기과학)-
dc.contributor.googleauthorSong Y.S.-
dc.contributor.googleauthorCho J.S.-
dc.contributor.googleauthorCho K.S.-
dc.contributor.googleauthorDoo S.H.-
dc.contributor.googleauthorChung B.H.-
dc.contributor.googleauthorKim S.J.-
dc.contributor.googleauthorYang W.J.-
dc.contributor.googleauthorSong K.H.-
dc.contributor.googleauthorKim C.I.-
dc.contributor.googleauthorHong S.J.-
dc.identifier.doi10.1159/000296294-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03607-
dc.contributor.localIdA03801-
dc.contributor.localIdA04402-
dc.relation.journalcodeJ02773-
dc.identifier.eissn1423-0399-
dc.identifier.pmid20234122-
dc.identifier.urlhttp://www.karger.com/Article/FullText/296294-
dc.subject.keywordTransitional cell carcinoma-
dc.subject.keywordChemotherapy-
dc.subject.keywordBladder-
dc.subject.keywordRenal pelvis-
dc.subject.keywordUreter-
dc.contributor.alternativeNameChung, Byung Ha-
dc.contributor.alternativeNameCho, Kang Su-
dc.contributor.alternativeNameHong, Sung Joon-
dc.contributor.affiliatedAuthorChung, Byung Ha-
dc.contributor.affiliatedAuthorCho, Kang Su-
dc.contributor.affiliatedAuthorHong, Sung Joon-
dc.citation.volume85-
dc.citation.number1-
dc.citation.startPage47-
dc.citation.endPage51-
dc.identifier.bibliographicCitationUROLOGIA INTERNATIONALIS, Vol.85(1) : 47-51, 2010-
dc.identifier.rimsid47795-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.